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Background: Systematic reviews have been challenged to consider effects on disadvantaged groups. A priori
specification of subgroup analyses is recommended to increase the credibility of these analyses. This study aimed
to develop and assess inter-rater agreement for an algorithm for systematic review authors to predict whether
differences in effect measures are likely for disadvantaged populations relative to advantaged populations (only
relative effect measures were addressed).
Methods: A health equity plausibility algorithm was developed using clinimetric methods with three items based
on literature review, key informant interviews and methodology studies. The three items dealt with the plausibility
of differences in relative effects across sex or socioeconomic status (SES) due to: 1) patient characteristics; 2)
intervention delivery (i.e., implementation); and 3) comparators. Thirty-five respondents (consisting of clinicians,
methodologists and research users) assessed the likelihood of differences across sex and SES for ten systematic
reviews with these questions. We assessed inter-rater reliability using Fleiss multi-rater kappa.
Results: The proportion agreement was 66% for patient characteristics (95% confidence interval: 61%-71%), 67% for
intervention delivery (95% confidence interval: 62% to 72%) and 55% for the comparator (95% confidence interval:
50% to 60%). Inter-rater kappa, assessed with Fleiss kappa, ranged from 0 to 0.199, representing very low agreement
beyond chance.
Conclusions: Users of systematic reviews rated that important differences in relative effects across sex and
socioeconomic status were plausible for a range of individual and population-level interventions. However, there
was very low inter-rater agreement for these assessments. There is an unmet need for discussion of plausibility of
differential effects in systematic reviews. Increased consideration of external validity and applicability to different
populations and settings is warranted in systematic reviews to meet this need.
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Health inequity is defined as avoidable and unfair differ-
ences in health [1]. Health inequity is caused by mul-
tiple, interacting factors described by the WHO
Commission on Social Determinants of Health (CSDH)
as 1) the socioeconomic and political context, 2) social
position, 3) material circumstances and 4) the health
system [2]. The health system described by the WHO
CSDH is a broad concept which includes factors such as
access to health care as well as the effectiveness of
health care as well as public health and non-health inter-
ventions. Health care, health policy and non-health (e.g.
social or financial) interventions may inadvertently
increase health inequity if they are less effective in dis-
advantaged populations due to either prognostic fac-
tors (e.g. comorbidities or nutritional deficiencies) or
treatment-covariate interactions (e.g. crowded home
environment may increase transmission of infectious
diseases, low literacy affects ability to benefit from
written materials) [3].
Systematic reviews are useful as a basis for evidence-
informed policy and practice [4,5]. Systematic reviews
represent an opportunity to identify what works to pro-
mote health equity because they include studies con-
ducted in a diversity of settings and populations
allowing both prognostic factors and treatment-covariate
interactions to be explored [6-8]. However, systematic
reviews rarely assess whether interventions have
intended or unintended effects on health equity. For ex-
ample, only 1% of a random sample of Cochrane reviews
assessed differences in effectiveness of interventions
across socioeconomic or demographic factors [9].
Decision-makers such as NICE (National Institute of
Clinical Excellence) in the UK and CADTH (Canadian
Agency for Drugs and Technology in Health) in Canada
are asking systematic reviews to assess the evidence of
differential effects across age, sex and socioeconomic
status. Failure to assess or consider effects on health
equity in systematic reviews may lead to rejection of
systematic reviews as a useful source of evidence for
policy-makers who seek information on distribution
of effects in the population [10,11], or may even lead
to implementation of policies and programs which
inadvertently increase health inequities [12,13].
Health inequity can be categorized using the
PROGRESS-Plus framework –this is an acronym which
summarizes factors across which differences in health
may be considered inequitable depending on the setting
and context: Place of residence; Race/ethnicity/culture;
Occupation; Gender; Religion; Education; Socioeco-
nomic status; Social capital [14]. There are additional
personal characteristics (e.g. age, disability and sexual
orientation) [15,16] that may present barriers to use of
health and other public services; some of which areincluded in antidiscrimination laws. Furthermore, add-
itional details may be helpful in describing vulnerable
people depending on the focus of the study. For ex-
ample, for studies of young people, additional character-
istics related to vulnerability may include exclusion from
school, looked after children or runaways. The term
PROGRESS-Plus was coined to be a more inclusive
framework for identifying both broad social and eco-
nomic determinants of health (PROGRESS) and other
characteristics, context and setting that are particularly
relevant to the focus of study (Plus) [15]. Promoting
health equity remains high on the agenda of local, na-
tional and international policy agendas [17].
Systematic reviews have been challenged to consider
whether disadvantaged groups will obtain the same or
more benefit than the mean effect, while at the same
time minimizing the risk of spurious results due to mul-
tiple comparisons[12]. One way to reduce the chances
of spurious results and increase the credibility of sub-
group analyses is to specify comparisons prior to analysis
[18-20] . Different authors are likely to argue pre-hoc for
different groups. Thus, there is a need to assess how
often there is disagreement amongst authors, and if so,
develop guidelines for making these judgments.
This study aimed to develop and evaluate an algorithm
to assess the likelihood of differences in relative effects
of interventions in disadvantaged populations (across
sex and socioeconomic status) relative to advantaged
populations.
Methods
The health equity plausibility algorithm was developed
using steps based on Feinstein [21] and Streiner and
Norman [22].
Ethics approval
This research study was approved by the University of
Ottawa Research Ethics Board (ethics approval certifi-
cate #H02-09-11b and #H02-09-11c).
Purpose
The purpose of the health equity plausibility algorithm is
to assess the likelihood of differences in relative effect of
an intervention across population characteristics defined
by PROGRESS-Plus. For example, aspirin reduces the
risk of stroke in women but not in men [23]. As another
example, the measles antibody response in children is
lower among the malnourished [23]. We chose to focus
on only two PROGRESS-Plus characteristics because we
felt that this would be a difficult task for respondents,
and multiple characteristics might lead to lack of atten-
tion to additional characteristics. We selected sex and
socioeconomic status because they are amongst the most
commonly reported differences in effects and burden of
Welch et al. BMC Medical Research Methodology 2012, 12:187 Page 3 of 9
http://www.biomedcentral.com/1471-2288/12/187disease in the literature, and we felt respondents would
feel the most able to make decisions about these charac-
teristics. We recognize that differences across other
characteristics such as ethnicity, educational attainment
and occupation are important but these have not been
assessed in this study.
It is important to note that the health equity plausibil-
ity algorithm is intended to predict likelihood of differ-
ences in relative but not absolute effects. Differences in
absolute effects can be artifacts of differences in baseline
risk, with no attendant difference in actual effect. For ex-
ample, immigrants and refugees have a lifetime risk of
developing active tuberculosis of over 35%. Assuming a
relative risk reduction with isoniazid treatment of 93%,
treating all immigrants and refugees will reduce lifetime
cases of active tuberculosis by 33 in 100 people. In con-
trast, the typical high income country-born population
has a low risk of developing latent tuberculosis: a typical
prevalence in this case would amount to only 5 in 100
people. In this case the absolute reduction in number of
cases with treatment would be only 2 per 100 people
[24]; the difference of 33 per 100 for refugees or immi-
grants compared to 2 per 100 for high-income country
born reflects a difference in baseline rates alone.
Item generation
Items were generated using three methods. First, existing
checklists for applicability, transferability and external
validity were assessed for factors related to judging likely
differences in relative effects (Additional file 1: Appendix
1). Second, factors associated with subgroup analyses
across PROGRESS-Plus were assessed in a systematic re-
view of methods for assessing effects on health equity
[25]. Third, practitioners and managers were interviewed
using convergent interviewing [26] to identify factors
associated with success or failure of program implemen-
tation in a vulnerable population [27].
Item reduction, questionnaire format, scaling, face
validity
One author (VW) developed a draft algorithm using the
above items. Items were phrased using wording from
previously published checklists where possible. Dichot-
omous yes/no categories were chosen for the responses
for two reasons: 1) a “don’t know” category was consid-
ered unhelpful in determining likelihood; and 2) the abil-
ity of respondents to discriminate more finely than yes/
no was uncertain. The draft algorithm was refined with
two other authors (PT and GW). The face and concep-
tual validity was tested by asking four clinician metho-
dologists with experience in clinical epidemiology,
systematic reviews and health equity to review the items
and judge their clarity and their ability to measure the
concept of interest, defined as assessing the likelihoodof differences in relative or absolute effects across
PROGRESS-Plus characteristics[21]. Subsequent pilot-
testing persuaded us to restrict attention to differences
in relative effects, thereby dropping further consider-
ation of absolute effects.
Consistency
Inter-rater reliability of the health equity plausibility al-
gorithm was assessed by recruiting methodologists, clini-
cians and users of systematic reviews to apply the health
equity plausibility algorithm to a sample of 10 systematic
reviews. Thirty-five respondents (methodologists, clini-
cians and users of systematic reviews) were recruited by
approaching members of the Cochrane Collaboration
who attended the 2009 annual Colloquium. Respondents
were asked to judge the likelihood of differences for two
PROGRESS-Plus items: 1) sex: female vs. male and 2)
low socioeconomic status vs. high socioeconomic status,
using the survey (Additional file 1: Appendix 2).
Raters were given a summary for each of 10 systematic
reviews inclusion criteria and methods for the popula-
tion, intervention, comparison, outcomes and study
designs included (columns 3–7 of Additional file 1: Ap-
pendix 3). Raters were not given the results of the sys-
tematic reviews.
The health equity plausibility algorithm was presented
to raters as a list of three questions on one page, with a
checkbox requiring Yes or No answers. Raters were also
given examples of how each of the factors might create
important differences in the magnitude of relative
effects, based on examples from the updated Journal of
American Medical Association (JAMA) User’s Guide on
applying results to individual patients [28].
Inter-rater agreement was assessed using Fleiss’ Kappa
for multiple raters for 60 assessments (10 systematic
reviews X 3 questions X 2 PROGRESS-Plus factors)
[29]. We also assessed and interpreted the proportion
agreement [30].
The ten systematic reviews chosen for the survey were
selected based on the following criteria: 1) proven effect-
ive and cost-effective interventions identified by the
WHO-CHOICE (World Health Organization CHoosing
Interventions that are Cost-Effective) initiative [31]; 2)
representation of different types of intervention using
the categories defined by the Disease Control Priorities
Project of: i) Population-based primary prevention; ii)
Personal interventions and iii) Policy instruments
[32]; 3) included in the top ten causes of the global
burden of disease projected for 2030 [33]; 4) availability
of a systematic review with greater than five included
studies including a diversity of settings and populations
(a meta-analysis was not required since differences
across populations can be assessed without a meta-
analysis). Candidate reviews were identified by searching
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reviews were chosen by discussion of two reviewers
(VW, PT) based on the above criteria. They included
nine Cochrane reviews and one non-Cochrane review.
The attribute of being Cochrane or non-Cochrane re-
views was not a criterion for selection since we did not
feel there would be important differences in how sys-
tematic reviews approach the issue of differences across
subgroups based on this attribute.Construct validity
The ideal test of construct validity of this health equity
plausibility algorithm is comparison with the criterion of
whether there are real differences in effects by sex and
socioeconomic status, irrespective of whether the instru-
ments (systematic reviews and underlying studies) are
able to detect these differences. Comparison to this cri-
terion would be considered concurrent validity. How-
ever, since we cannot know the real intervention effects,
we used a proxy by considering the results and discus-
sion of the systematic reviews as an indicator of real dif-
ferences in effects and compared this with the health
equity plausibility algorithm to assess construct validity.
We extracted these details from the discussion sections
of each systematic review by assessing any mention of
differences across PROGRESS Plus factors, whether they
were supported by evidence or not (e.g. hypothesized
differences not supported by evidence were included).
We recognize that systematic reviews and underlying
primary studies may not be designed or powered to
detect such differences (column 2 of Additional file 1:
Appendix 3). Therefore, the construct validity of the
health equity plausibility algorithm was assessed by com-
paring whether raters’ assessment of likelihood of im-
portant differences in effects were concordant with
the discussion of applicability and generalizability by
the authors of the systematic reviews across sex and
socioeconomic status. Only those comparisons where
70% of raters gave the same judgment were compared
with the systematic review conclusions about applic-
ability and generalizability. This cut-off of 70% was
chosen based on use of this criterion for consensus
recommendations [34].Table 1 Health equity plausibility algorithm questions
Question 1: Are there differences in patient/community/ population cha
attitudes, etc.) that are likely to create important differences
for the outcome of interest?
Question 2: Are there differences in the way that the intervention is del
availability of drugs/treatments) that are likely to create imp
intervention versus the control for the outcome of interest?
Question 3: Are there differences in the comparator across patient, com
magnitude of relative effects?Results
Item generation
A draft health equity plausibility algorithm was devel-
oped by three authors (VW,GW,PT) that consisted of
four yes/no items: 1) differences in implementation fac-
tors across PROGRESS-Plus (e.g. differences in
resources); 2) likelihood of variations in the delivery of
the intervention across PROGRESS-Plus (e.g. because of
poor acceptability, inappropriate literacy level); 3) differ-
ent mechanism of action of the intervention across
PROGRESS-Plus; and 4) differences in expected absolute
effects because of higher risk or prevalence across
PROGRESS-Plus.
Item reduction, questionnaire format, scaling, face
validity
Consultation with five content experts resulted in adding
an item about possible differences in the comparator
that might lead to differences in effectiveness. Differ-
ences in comparator was defined as whether the “con-
trol” groups differed in the context of the systematic
review studies compared to the context to which the
results would be applied. A question about absolute
effects was removed, since it did not fit with the focus of
this checklist to identify likelihood of differences in rela-
tive effects across PROGRESS-Plus. The revised health
equity plausibility algorithm consisted of three questions
(Table 1).
Inter-rater consistency
Ten systematic reviews were selected for the field test
(Additional file 1: Appendix 3): 1) mass media to pro-
mote HIV testing [35]; 2) Population level tobacco con-
trol [36]; 3) psychological therapy for post-traumatic
stress disorder [37]; 4) first-line anti-hypertensive drugs
for people with hypertension [38]; 5) surgical interven-
tions for age-related cataract [39]; 6) vaccines for mea-
sles, mumps and rubella [40]; 7) antidepressants vs.
placebo in primary care [41]; 8) artemisinin-based com-
bination therapy for uncomplicated malaria [42]; 9) pri-
mary safety belt laws [43]; and 10) handwashing for the
prevention of diarrhea episodes [44].
Of 43 people contacted, 35 filled out the questionnaire
(participation rate= 81%). The 35 respondentsracteristics (e.g. underlying pathophysiology, comorbidities, patient
in the magnitude of relative effect of the intervention versus the control
ivered (e.g. provider compliance, provider skill, technical resources,
ortant differences in the magnitude of the relative effect of the
munity or population that are likely to create important differences in
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cians with a median of 7 years of experience using or
conducting systematic reviews and diverse clinical ex-
perience (e.g. public health, musculoskeletal, dermatol-
ogy, cancer, infectious disease) (Table 2). No questions
were skipped.Table 3 Sex/Gender: Health equity plausibility ratings for eac
Sex: Proportion judging important differences







INTER-RATER AGREEMENT on Q1 ≥70%







Vaccines for MMR in
children
8% 17% 25%

















ACT for malaria 33% 33% 25%
Fleiss Kappa 0.199 0.068 0.005
Notes: PTSD: Post-traumatic stress disorder; SES: socioeconomic status; MMR: MeaslFor the decision about whether important differences
existed across sex (e.g. between males and females), the
proportion agreement was 66% for patient characteris-
tics, 54% for intervention delivery, and 51% for compara-
tor. Across socioeconomic status, the proportion
agreement was 66% for patient characteristics, 79% for
intervention delivery, and 59% for comparator. The
Fleiss kappa for multiple raters ranged from −0.001 to
0.199 (Table 3 and 4). A kappa of less than 0.2 is consid-
ered slight agreement [45], with kappa of 0.2<k<0.4 con-
sidered fair; 0.4<k<0.6 moderate, 0:6<k<0.8 substantial
and k>0.8 almost perfect agreement.
As part of the survey, respondents were asked to ex-
plain the reasoning behind their answers (Table 5). The
most common reasons for the answers were based on
theory (n=10 raters) and personal experience (n=11).
Other reasons for ratings were empirical data (n= 3) and
“guesses” (n=4) (8). Respondents stated that other infor-
mation would have been useful to complete the task, in-
cluding more information about the interventions and
outcomes, clarity on the comparator question and details
on the size of difference considered important. Almost
one third (10/35) of raters endorsed the importance of
considering differences across PROGRESS-Plus in the




Description in systematic review
Sex differences not analyzed or discussed
Sex not discussed or analyzed
Sex not discussed or analyzed.
Men have higher uptake of seatbelts
Studies including only females, all of whom had been assaulted,
produced more positive results than the overall results.
No differences found across sex
Females represented 45% of population. No subgroup analyses
conducted on sex
Sex not discussed
Analyses were age and sex adjusted, differences not discussed
Sex not discussed
es, mumps and rubella vaccine.
Table 4 Socioeconomic status (SES): Proportion of respondents judging important differences exist for each question,
across 10 systematic reviews











Description in systematic review
INTER-RATER AGREEMENT on Q1 ≥70%
Mass media for HIV
testing
87% 100% 83% 78% Radio and television interventions can be used in literate and




84% 92% 92% 67% SES not discussed
Population tobacco
control
84% 91% 74% 87% Price increases are more effective in low-income populations.
Smoking restrictions: no SES differences
Hand washing for
preventing diarrhoea
89% 83% 92% 92% SES not discussed
INTER-RATER AGREEMENT on Q1 <70%
Surgery for age-related
cataract
86% 75% 100% 83% In developing countries, access to expensive machines,
volume of surgeries and skill of surgeons may be lower
Psychological therapy
for PTSD
75% 78% 91% 57% SES not discussed
ACT for malaria 72% 75% 92% 50% SES not discussed
Primary safety belt laws 72% 58% 100% 58% More effective for lower use groups (e.g. African-American
and Hispanic in USA)
First line anti-
hypertensives
67% 65% 83% 52% SES differences not assessed.
Vaccines MMR in
children
67% 50% 75% 75% SES not discussed. “effectiveness demonstrated world-wide”
Fleiss Kappa −0.001 0.105 0.04
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Our proxy for a “gold standard,” namely a discussion
of differences in effect across sex or socioeconomic sta-
tus appearing in the conclusions of systematic reviews
is presented in Additional file 1: Appendix 3, column
1. Each of the ten systematic reviews discussed plausi-
bility of different effects for at least one of three fac-
tors: patient characteristics, intervention delivery or
comparator. For example, the review of primary safety
belt laws discussed greater effects in low use groups,
including men, Hispanics and African-Americans. The
tobacco control review assessed and found no differ-
ences across sex. It is important to note that some of
the systematic reviews mentioned differences across
PROGRESS-Plus factors, even though they were not
supported by evidence. For example, the mass media
review mentioned differences between literate and non-
literate populations, but this interpretation was not
supported by their data no part of any subgroup
analyses.
Thirty-two assessments out of 60 (53%) attained
greater than 70% agreement between raters (bolded text
in Additional file 1: Appendix 4). Of those assessments,
28/31 agreed that differences were likely; 3/31 agreed
that difference in effects was unlikely.The type of intervention did not seem to be associated
with agreement. Of those systematic reviews with greater
than 70% agreement on the first question on patient
characteristics, two were pharmacologic interventions
(vaccines and antidepressants) and three were behav-
ioural interventions (PTSD, safety belt laws and mass
media) (Table 5).
Agreement with conclusions of systematic reviews
Seventeen of the assessments with greater than 70%
inter-rater agreement (17/32; 53%) were concordant with
our proxy for construct validity (the judgments of ap-
plicability described by the authors of the systematic
reviews). For example, differences in effects due to pa-
tient characteristics (question 1) was judged likely for
population tobacco control across socioeconomic status,
which is supported by the conclusions of the systematic
review that state that price control is more effective for
low income populations [7].
Eight of the assessments (8/32; 25%) which reached
greater than 70% agreement between raters were not
consistent with the judgments of the authors of the sys-
tematic reviews.
Seven out of 32 assessments (22%) were classified as
agreement “Not Known” since the systematic reviews








more intervention specific information and data
how big are the differences being sought?
how does comparator overlap with intervention
delivery
was information available from trials?
consider including community cluster trials




Important to consider these issues in design of SR-5
Difficult- 4;
Interesting to consider these issues-5;
Subjective-6;
Why only gender and SES- need to consider other
factors (e.g. sexual orientation)- 2
Country differences are important- e.g. if universal
drug coverage is available-1
Accessibility of drugs is less of an issue-1
Ask questions about heterogeneity-1
Intervention delivery is important for understanding
Easy-1
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example, 91% of raters judged that important differences
were likely across SES due to delivery factors for PTSD,
but this was not discussed in the systematic review.Discussion
The three questions used for this study were derived
from questions which are given to users of systematic
reviews to make judgments about clinical practice impli-
cations, such as in the JAMA User’s Guide [28]. Al-
though a high proportion of participants rated
differences likely across socioeconomic status and sex,
the Fleiss kappa indicated low to no agreement beyond
chance between raters. Low kappa values in the presence
of high agreement has been called one of the paradoxes
of kappa [30,45]. Low kappa values may also indicate
that there was low contrast in the systematic reviews or
the raters, or that some systematic reviews were easier
to agree on than others [46]. The low kappa in this study
suggest that when making judgments about likely differ-
ences in effects, there is a need to have a deep under-
standing of the content area to make these ratings, and
may require the involvement of multiple stakeholders.
This has implications for the design of systematic review
author teams and advisory boards, as well as for how to
form panels of people who make judgments aboutapplicability for the purpose of guidelines or policy
decisions.
Secondly, the low kappa observed may be due to
multi-component questions covering several factors, and
potential confusion of access to health care, prognostic
factors and treatment-covariate interactions. Since these
three items were derived from questions recommended
to users of systematic reviews, this study suggests a need
to further refine these questions to improve understand-
ing and increase inter-rater agreement beyond chance.
The strengths of this study are that it followed estab-
lished steps in developing a checklist of item generation,
pilot-testing and assessed consistency and construct val-
idity in a field study. We selected systematic reviews for
the field study based on predetermined criteria to
maximize diversity of types of interventions (personal
and population level) and disease areas with greater than
five included studies including a diversity of settings and
populations. These ten systematic reviews also included
a mix of plausibility of different effects across the three
questions.
This study is subject to some limitations. Firstly, the
high proportion of “yes” answers may have been due to
the way the questions were framed. Secondly, the ration-
ale for affirmative responses was assessed by self-report
on a questionnaire, and few details were provided by
raters regarding how theory, data or personal experience
was used to make these judgments. Thus, we could not
assess whether differences were due to some of the rea-
sons that we expected such as the type of study design
(randomized vs. observational) or type of comparator
(placebo vs. control). Also, given that personal experi-
ence was the most common reason for ratings, the raters
individual characteristics may be important (e.g. whether
they are women, low income, immigrants), and this
could be explored in future studies. Both of these limita-
tions could be assessed in further detail by cognitive
interviewing using think out loud protocols to assess
how respondents interpreted the questions and could be
used to improve the questions [47]. Another possible
limitation is the use of only two categories (yes/no), and
the omission of a “don’t know” category. Raters may
have resorted to personal value judgments or random
guesses when forced to choose between “yes” and “no”.
This might be addressed in future research by using
more categories to reflect strong agreement to strong
disagreement or by using a visual analogue scale; either
of these methods would allow an assessment of confi-
dence of raters in the importance of the difference. Fi-
nally, we recognize that our proxy for construct validity
yielded unsatisfactory results. We suggest that this indi-
cates a need for improved consideration and reporting
of applicability in systematic reviews, particularly for
populations to whom the results are likely to be applied.
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This study reinforces the need to develop, evaluate and
promote structured methods for considering applicabil-
ity to relevant populations in systematic reviews. The
low kappa suggests a need for a depth of content expert-
ise and stakeholders on systematic review author teams
in making such decisions. The results also suggest a
need to improve the clarity of questions intended to help
users of systematic reviews make applicability judg-
ments. Planning and design of primary research studies
and trials needs to take into account whether there are
expected and plausible differences across population
groups such as sex using appropriate methods such as
stratification and pre-planned subgroup analyses.. The
Campbell and Cochrane Equity Methods Group is con-
ducting methodological research on methods such as
the use of logic models, subgroup analysis, applicability
judgments and process evaluation as tools for assessing
the plausibility of effects on health equity [48].
Additional file
Additional file 1: Appendix 1. Applicability and transferability checklists
[49-60]. Appendix 2 Sample equity plausibility algorithm survey provided
to raters. Appendix 3 Characteristics of systematic reviews chosen for
testing the equity plausibility algorithm [61]. Appendix 4 Agreement of
equity plausibility ratings between raters for each question and
PROGRESS factor, across 10 systematic reviews.
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